Recherche
Résultats 1-10 de 17
-
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Journal of clinical oncology, 2017, 35, 2473Article dans une revue scientifique -
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma
American journal of hematology, 2016, 91, 179-184Article dans une revue scientifique -
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Lancet (London, England), 2016, 387, 2402-2411Article dans une revue scientifique -
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
The Lancet. Oncology, 2015, 16, 704-715Article dans une revue scientifique -
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
Leukemia, 2018Article dans une revue scientifique -
Through the Glass Ceiling.
Journal of clinical oncology, 2018, JCO2017763961Article dans une revue scientifique -
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular b-cell lymphoma (galen): a multicentre, single-arm, phase 2 study
The Lancet. Haematology, 08-07-2019Article dans une revue scientifique -
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-hodgkin lymphoma: final results from a phase 2 randomised study (romulus)
The Lancet. Haematology, 29-03-2019Article dans une revue scientifique -
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
The New England journal of medicine, 2018, 379, 934-947Article dans une revue scientifique -
Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study
The Lancet. Haematology, 2018, 5, E403-E410Article dans une revue scientifique